Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs

European Journal of Cancer

Volumn 71, Issue , 2017, Pages 53-69

  Schadendorf, Dirk ^a   Lebbé, Céleste ^b   zur Hausen, Axel ^c   Avril, Marie Françoise ^d   Hariharan, Subramanian ^e   Bharmal, Murtuza ^f   Becker, Jürgen C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b INSERM   (France)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Institut Cochin   (France)

^e PFIZER INC   (United States)

^f MERCK KGAA   (Germany)

Author keywords

Epidemiology; Merkel cell carcinoma; Merkel cell polyomavirus; Prognosis; Skin cancer; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; PHOSPHOTRANSFERASE INHIBITOR; SOMATOSTATIN DERIVATIVE; TUMOR MARKER;

ADOPTIVE IMMUNOTHERAPY; AGE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; HEALTH CARE NEED; HISTOPATHOLOGY; HUMAN; IMMUNE STATUS; IMMUNOSUPPRESSIVE TREATMENT; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT REFERRAL; PHASE 2 CLINICAL TRIAL (TOPIC); POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; REVIEW; SEX; T LYMPHOCYTE; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; ADVERSE EFFECTS; CARCINOMA, MERKEL CELL; COMPLICATION; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; SKIN NEOPLASMS; VIRUS INFECTION;

AGE FACTORS; ANTINEOPLASTIC AGENTS; CARCINOMA, MERKEL CELL; COMBINED MODALITY THERAPY; HUMANS; POLYOMAVIRUS INFECTIONS; PROGNOSIS; RISK FACTORS; SEX FACTORS; SKIN NEOPLASMS; TUMOR VIRUS INFECTIONS; ULTRAVIOLET RAYS;

EID: 85004008122     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.10.022     Document Type: Review

References (173)

1. [1] Toker, C., Trabecular carcinoma of the skin. Arch Dermatol 105:1 (1972 Jan), 107–110.
2. [2] Houben, R., Schrama, D., Becker, J.C., Molecular pathogenesis of Merkel cell carcinoma. Exp Dermatol 18:3 (2009 Mar), 193–198.
3. [3] Miller, R.W., Rabkin, C.S., Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev 8:2 (1999 Feb), 153–158.
4. [4] Heath, M., Jaimes, N., Lemos, B., Mostaghimi, A., Wang, L.C., Penas, P.F., et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 58:3 (2008 Mar), 375–381.
5. [5] Allen, P.J., Bowne, W.B., Jaques, D.P., Brennan, M.F., Busam, K., Coit, D.G., Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 23:10 (2005 Apr 1), 2300–2309.
6. [6] Agelli, M., Clegg, L.X., Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 49:5 (2003 Nov), 832–841.
7. [7] Fitzgerald, T.L., Dennis, S., Kachare, S.D., Vohra, N.A., Wong, J.H., Zervos, E.E., Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. Am Surg 81:8 (2015 Aug), 802–806.
8. [8] Eng, T.Y., Boersma, M.G., Fuller, C.D., Cavanaugh, S.X., Valenzuela, F., Herman, T.S., Treatment of Merkel cell carcinoma. Am J Clin Oncol 27:5 (2004 Oct), 510–515.
9. [9] Gupta, S.G., Wang, L.C., Penas, P.F., Gellenthin, M., Lee, S.J., Nghiem, P., Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: the Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 142:6 (2006 Jun), 685–690.
10. [10] Kempf, W., Mertz, K.D., Hofbauer, G.F., Tinguely, M., Skin cancer in organ transplant recipients. Pathobiology 80:6 (2013), 302–309.
11. [11] Engels, E.A., Frisch, M., Goedert, J.J., Biggar, R.J., Miller, R.W., Merkel cell carcinoma and HIV infection. Lancet 359:9305 (2002 Feb 9), 497–498.
12. [12] Lanoy, E., Costagliola, D., Engels, E.A., Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. Int J Cancer 126:7 (2010 Apr 1), 1724–1731.
13. [13] Lanoy, E., Dores, G.M., Madeleine, M.M., Toro, J.R., Fraumeni, J.F. Jr., Engels, E.A., Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS 23:3 (2009 Jan 28), 385–393.
14. [14] Kaae, J., Hansen, A.V., Biggar, R.J., Boyd, H.A., Moore, P.S., Wohlfahrt, J., et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst 102:11 (2010 Jun 2), 793–801.
15. [15] Brenner, B., Sulkes, A., Rakowsky, E., Feinmesser, M., Yukelson, A., Bar-Haim, E., et al. Second neoplasms in patients with Merkel cell carcinoma. Cancer 91:7 (2001 Apr 1), 1358–1362.
16. [16] Feng, H., Shuda, M., Chang, Y., Moore, P.S., Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:5866 (2008 Feb 22), 1096–1100.
17. [17] Goh, G., Walradt, T., Markarov, V., Blom, A., Riaz, N., Doumani, R., et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 7:3 (2016 Jan 19), 3403–3415.
18. [18] Wong, S.Q., Waldeck, K., Vergara, I.A., Schroder, J., Madore, J., Wilmott, J.S., et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res 75:24 (2015 Dec 15), 5228–5234.
19. [19] van der Zwan, J.M., Trama, A., Otter, R., Larranaga, N., Tavilla, A., Marcos-Gragera, R., et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer 49:11 (2013 Jul), 2565–2578.
20. [20] Youlden, D.R., Soyer, H.P., Youl, P.H., Fritschi, L., Baade, P.D., Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993–2010. JAMA Dermatol 150:8 (2014 Aug), 864–872.
21. [21] Becker, J.C., Merkel cell carcinoma. Ann Oncol, 21(Suppl. 7), 2010 Oct vii81-5.
22. [22] Lemos, B.D., Storer, B.E., Iyer, J.G., Phillips, J.L., Bichakjian, C.K., Fang, L.C., et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 63:5 (2010 Nov), 751–761.
23. [23] Santamaria-Barria, J.A., Boland, G.M., Yeap, B.Y., Nardi, V., Dias-Santagata, D., Cusack, J.C. Jr., Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol 20:4 (2013 Apr), 1365–1373.
24. [24] National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Merkel Cell Carcinoma. 2016.
25. [25] Lebbe, C., Becker, J.C., Grob, J.J., Malvehy, J., Del Marmol, V., Pehamberger, H., et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer 51:16 (2015 Aug 6), 2396–2403.
26. [26] Smith, V.A., Camp, E.R., Lentsch, E.J., Merkel cell carcinoma: identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data. Laryngoscope 122:6 (2012 Jun), 1283–1290.
27. [27] Hussain, S.K., Sundquist, J., Hemminki, K., Incidence trends of squamous cell and rare skin cancers in the Swedish national cancer registry point to calendar year and age-dependent increases. J Invest Dermatol 130:5 (2010 May), 1323–1328.
28. [28] Medina-Franco, H., Urist, M.M., Fiveash, J., Heslin, M.J., Bland, K.I., Beenken, S.W., Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 8:3 (2001 Apr), 204–208.
29. [29] Jaeger, T., Ring, J., Andres, C., Histological, immunohistological, and clinical features of Merkel cell carcinoma in correlation to Merkel cell polyomavirus status. J Skin Cancer, 2012, 983421.
30. [30] Bichakjian, C.K., Lowe, L., Lao, C.D., Sandler, H.M., Bradford, C.R., Johnson, T.M., et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 110:1 (2007 Jul 1), 1–12.
31. [31] Trenkic Bozinovic, M., Krasic, D., Katic, V., Rancic, D., Krstic, M., Jocic Djordjevic, J., et al. Comparative analysis of clinicopathological and immunohistochemical characteristics of Merkel cell carcinoma. J BUON 19:2 (2014 Apr–Jun), 530–534.
32. [32] Poulsen, M., Merkel cell carcinoma of skin: diagnosis and management strategies. Drugs Aging 22:3 (2005), 219–229.
33. [33] Gu, J., Polak, J.M., Van Noorden, S., Pearse, A.G., Marangos, P.J., Azzopardi, J.G., Immunostaining of neuron-specific enolase as a diagnostic tool for Merkel cell tumors. Cancer 52:6 (1983 Sep 15), 1039–1043.
34. [34] Hanly, A.J., Elgart, G.W., Jorda, M., Smith, J., Nadji, M., Analysis of thyroid transcription factor-1 and cytokeratin 20 separates Merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol 27:3 (2000 Mar), 118–120.
35. [35] Allen, P.J., Zhang, Z.F., Coit, D.G., Surgical management of Merkel cell carcinoma. Ann Surg 229:1 (1999 Jan), 97–105.
36. [36] Clark, J.R., Veness, M.J., Gilbert, R., O'Brien, C.J., Gullane, P.J., Merkel cell carcinoma of the head and neck: is adjuvant radiotherapy necessary?. Head Neck 29:3 (2007 Mar), 249–257.
37. [37] Yiengpruksawan, A., Coit, D.G., Thaler, H.T., Urmacher, C., Knapper, W.K., Merkel cell carcinoma. Prognosis and management. Arch Surg 126:12 (1991 Dec), 1514–1519.
38. [38] Edge, S.B., Compton, C.C., The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:6 (2010 Jun), 1471–1474.
39. [39] Harms, K.L., Healy, M.A., Nghiem, P., Sober, A.J., Johnson, T.M., Bichakjian, C.K., et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann Surg Oncol 23:11 (2016 Oct), 3564–3571.
40. [40] Jabbour, J., Cumming, R., Scolyer, R.A., Hruby, G., Thompson, J.F., Lee, S., Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early stage disease–results from a review of 82 consecutive cases diagnosed between 1992 and 2004. Ann Surg Oncol 14:6 (2007 Jun), 1943–1952.
41. [41] Voog, E., Blay, J.Y., Merkel cell carcinoma: diagnostic and treatment. Bull Cancer 86:7–8 (1999 Jul-Aug), 625–630.
42. [42] Fields, R.C., Busam, K.J., Chou, J.F., Panageas, K.S., Pulitzer, M.P., Allen, P.J., et al. Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma. Cancer 118:13 (2012 Jul 1), 3311–3320.
43. [43] Becker, J.C., zur Hausen, A., Cells of origin in skin cancer. J Invest Dermatol 134:10 (2014 Oct), 2491–2493.
44. [44] Jankowski, M., Kopinski, P., Schwartz, R., Czajkowski, R., Merkel cell carcinoma: is this a true carcinoma?. Exp Dermatol 23:11 (2014 Nov), 792–794.
45. [45] Carter, J.J., Paulson, K.G., Wipf, G.C., Miranda, D., Madeleine, M.M., Johnson, L.G., et al. Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst 101:21 (2009 Nov 4), 1510–1522.
46. [46] Tolstov, Y.L., Pastrana, D.V., Feng, H., Becker, J.C., Jenkins, F.J., Moschos, S., et al. Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer 125:6 (2009 Sep 15), 1250–1256.
47. [47] Tolstov, Y.L., Knauer, A., Chen, J.G., Kensler, T.W., Kingsley, L.A., Moore, P.S., et al. Asymptomatic primary Merkel cell polyomavirus infection among adults. Emerg Infect Dis 17:8 (2011 Aug), 1371–1380.
48. [48] Pastrana, D.V., Tolstov, Y.L., Becker, J.C., Moore, P.S., Chang, Y., Buck, C.B., Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog, 5(9), 2009 Sep, e1000578.
49. [49] Rodig, S.J., Cheng, J., Wardzala, J., DoRosario, A., Scanlon, J.J., Laga, A.C., et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 122:12 (2012 Dec), 4645–4653.
50. [50] Kassem, A., Schopflin, A., Diaz, C., Weyers, W., Stickeler, E., Werner, M., et al. Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res 68:13 (2008 Jul 1), 5009–5013.
51. [51] Becker, J.C., Houben, R., Ugurel, S., Trefzer, U., Pfohler, C., Schrama, D., MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol 129:1 (2009 Jan), 248–250.
52. [52] Laude, H.C., Jonchere, B., Maubec, E., Carlotti, A., Marinho, E., Couturaud, B., et al. Distinct Merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with Merkel cell carcinoma. PLoS Pathog, 6(8), 2010 Aug 26, e1001076.
53. [53] Houben, R., Shuda, M., Weinkam, R., Schrama, D., Feng, H., Chang, Y., et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 84:14 (2010 Jul), 7064–7072.
54. [54] Agelli, M., Clegg, L.X., Becker, J.C., Rollison, D.E., The etiology and epidemiology of Merkel cell carcinoma. Curr Probl Cancer 34:1 (2010 Jan-Feb), 14–37.
55. [55] Harms, P.W., Patel, R.M., Verhaegen, M.E., Giordano, T.J., Nash, K.T., Johnson, C.N., et al. Distinct gene expression profiles of viral- and nonviral-associated Merkel cell carcinoma revealed by transcriptome analysis. J Invest Dermatol 133:4 (2013 Apr), 936–945.
56. [56] Harms, P.W., Vats, P., Verhaegen, M.E., Robinson, D.R., Wu, Y.M., Dhanasekaran, S.M., et al. The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res 75:18 (2015 Sep 15), 3720–3727.
57. [57] Shuda, M., Feng, H., Kwun, H.J., Rosen, S.T., Gjoerup, O., Moore, P.S., et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA 105:42 (2008 Oct 21), 16272–16277.
58. [58] Koljonen, V., Kukko, H., Pukkala, E., Sankila, R., Bohling, T., Tukiainen, E., et al. Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma. Br J Cancer 101:8 (2009 Oct 20), 1444–1447.
59. [59] Paulson, K.G., Iyer, J.G., Blom, A., Warton, E.M., Sokil, M., Yelistratova, L., et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol 133:3 (2013 Mar), 642–646.
60. [60] Cutaneous neuroendocrine carcinoma, 2007 http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=11166&Disease_Disease_Search_diseaseGroup=Cutaneous-neuroendocrine-carcinoma&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Cutaneous-neuroendocrine-carcinoma&title=Cutaneous-neuroendocrine-carcinoma&search=Disease_Search_Simple [Accessed 08 August 2016].
61. [61] American Cancer Society, Key statistics for Merkel cell carcinoma. 2016 http://www.cancer.org/cancer/skincancer-Merkelcell/detailedguide/skin-cancer-Merkel-cell-carcinoma-key-statistics [Accessed 08 August 2016].
62. [62] National Cancer Registration and Analysis Service, Rare skin cancer in England. 2010 http://www.ncin.org.uk/publications/data_briefings/rareskincancer [Accessed 08 August 16].
63. [63] Riou-Gotta, M.O., Fournier, E., Danzon, A., Pelletier, F., Levang, J., Mermet, I., et al. Rare skin cancer: a population-based cancer registry descriptive study of 151 consecutive cases diagnosed between 1980 and 2004. Acta Oncol 48:4 (2009), 605–609.
64. [64] Mills, L.A., Durrani, A.J., Watson, J.D., Merkel cell carcinoma in south east Scotland, 1993–2003. Surgeon 4:3 (2006 Jun), 133–138.
65. [65] Eisemann, N., Waldmann, A., Geller, A.C., Weinstock, M.A., Volkmer, B., Greinert, R., et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol 134:1 (2014 Jan), 43–50.
66. [66] Reichgelt, B.A., Visser, O., Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993–2007. Eur J Cancer 47:4 (2011 Mar), 579–585.
67. [67] Robertson, J.P., Liang, E.S., Martin, R.C., Epidemiology of Merkel cell carcinoma in New Zealand: a population-based study. Br J Dermatol 173:3 (2015 Mar 20), 835–837.
68. [68] Hodgson, N.C., Merkel cell carcinoma: changing incidence trends. J Surg Oncol 89:1 (2005 Jan 1), 1–4.
69. [69] Lyhne, D., Lock-Andersen, J., Dahlstrom, K., Drzewiecki, K.T., Balslev, E., Muhic, A., et al. Rising incidence of Merkel cell carcinoma. J Plast Surg Hand Surg 45:6 (2011 Dec), 274–280.
70. [70] Girschik, J., Thorn, K., Beer, T.W., Heenan, P.J., Fritschi, L., Merkel cell carcinoma in western Australia: a population-based study of incidence and survival. Br J Dermatol 165:5 (2011 Nov), 1051–1057.
71. [71] Chun, S.M., Yun, S.J., Lee, S.C., Won, Y.H., Lee, J.B., Merkel cell polyomavirus is frequently detected in Korean patients with Merkel cell carcinoma. Ann Dermatol 25:2 (2013 May), 203–207.
72. [72] Hattori, T., Takeuchi, Y., Takenouchi, T., Hirofuji, A., Tsuchida, T., Kabumoto, T., et al. The prevalence of Merkel cell polyomavirus in Japanese patients with Merkel cell carcinoma. J Dermatol Sci 70:2 (2013 May), 99–107.
73. [73] Song, P.I., Liang, H., Wei, W.Q., Jiang, Y.Q., Smith, J.S., Qiao, Y.L., The clinical profile of Merkel cell carcinoma in mainland China. Int J Dermatol 51:9 (2012 Sep), 1054–1059.
74. [74] Albores-Saavedra, J., Batich, K., Chable-Montero, F., Sagy, N., Schwartz, A.M., Henson, D.E., Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population-based study. J Cutan Pathol 37:1 (2010 Jan), 20–27.
75. [75] Agbai, O.N., Buster, K., Sanchez, M., Hernandez, C., Kundu, R.V., Chiu, M., et al. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol 70:4 (2014 Apr), 748–762.
76. [76] Koksal, Y., Toy, H., Talim, B., Unal, E., Akcoren, Z., Cengiz, M., Merkel cell carcinoma in a child. J Pediatr Hematol Oncol 31:5 (2009 May), 359–361.
77. [77] Marzban, S., Geramizadeh, B., Farzaneh, M.R., Merkel cell carcinoma in a 17-year-old boy, report of a highly aggressive fatal case and review of the literature. Rare Tumors, 3(3), 2011 Jul 11, e34.
78. [78] Grabowski, J., Saltzstein, S.L., Sadler, G.R., Tahir, Z., Blair, S., A comparison of Merkel cell carcinoma and melanoma: results from the California Cancer Registry. Clin Med Oncol 2 (2008), 327–333.
79. [79] Asgari, M.M., Sokil, M.M., Warton, E.M., Iyer, J., Paulson, K.G., Nghiem, P., Effect of host, tumor, diagnostic, and treatment variables on outcomes in a large cohort with Merkel cell carcinoma. JAMA Dermatol 150:7 (2014 Jul), 716–723.
80. [80] Samimi, M., Touze, A., Laude, H., Le Bidre, E., Arnold, F., Carpentier, A., et al. Vitamin D deficiency is associated with greater tumor size and poorer outcome in Merkel cell carcinoma patients. J Eur Acad Dermatol Venereol 28:3 (2014 Mar), 298–308.
81. [81] Saxena, A., Rubens, M., Ramamoorthy, V., Khan, H., Risk of second cancers in Merkel cell carcinoma: a meta-analysis of population-based cohort studies. J Skin Cancer, 2014, 184245.
82. [82] Brewer, J.D., Shanafelt, T.D., Otley, C.C., Roenigk, R.K., Cerhan, J.R., Kay, N.E., et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol 30:8 (2012 Mar 10), 843–849.
83. [83] Sihto, H., Kukko, H., Koljonen, V., Sankila, R., Bohling, T., Joensuu, H., Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst 101:13 (2009 Jul 1), 938–945.
84. [84] Bhatia, K., Goedert, J.J., Modali, R., Preiss, L., Ayers, L.W., Merkel cell carcinoma subgroups by Merkel cell polyomavirus DNA relative abundance and oncogene expression. Int J Cancer 126:9 (2010 May 1), 2240–2246.
85. [85] Handschel, J., Muller, D., Depprich, R.A., Ommerborn, M.A., Kubler, N.R., Naujoks, C., et al. The new polyomavirus (MCPyV) does not affect the clinical course in MCCs. Int J Oral Maxillofac Surg 39:11 (2010 Nov), 1086–1090.
86. [86] Schrama, D., Becker, J.C., Merkel cell carcinoma–pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 25:10 (2011 Oct), 1121–1129.
87. [87] Higaki-Mori, H., Kuwamoto, S., Iwasaki, T., Kato, M., Murakami, I., Nagata, K., et al. Association of Merkel cell polyomavirus infection with clinicopathological differences in Merkel cell carcinoma. Hum Pathol 43:12 (2012 Dec), 2282–2291.
88. [88] Afanasiev, O.K., Yelistratova, L., Miller, N., Nagase, K., Paulson, K., Iyer, J.G., et al. Merkel polyomavirus-specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and tim-3 exhaustion markers. Clin Cancer Res 19:19 (2013 Oct 1), 5351–5360.
89. [89] Paulson, K.G., Iyer, J.G., Tegeder, A.R., Thibodeau, R., Schelter, J., Koba, S., et al. Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 29:12 (2011 Apr 20), 1539–1546.
90. [90] Paulson, K.G., Iyer, J.G., Simonson, W.T., Blom, A., Thibodeau, R.M., Schmidt, M., et al. CD8+ lymphocyte intratumoural infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. Am J Clin Pathol 142:4 (2014 Oct), 452–458.
91. [91] Sihto, H., Joensuu, H., Tumor-infiltrating lymphocytes and outcome in Merkel cell carcinoma, a virus-associated cancer. Oncoimmunology 1:8 (2012 Nov 1), 1420–1421.
92. [92] Feldmeyer, L., Hudgens, C.W., Lyons, G.R., Nagarajan, P., Aung, P.P., Curry, J.L., et al. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. Clin Cancer Res, 2016 May 10, 10.1158/1078-0432.CCR-16-0392.
93. [93] Touze, A., Le Bidre, E., Laude, H., Fleury, M.J., Cazal, R., Arnold, F., et al. High levels of antibodies against Merkel cell polyomavirus identify a subset of patients with Merkel cell carcinoma with better clinical outcome. J Clin Oncol 29:12 (2011 Apr 20), 1612–1619.
94. [94] Samimi, M., Molet, L., Fleury, M., Laude, H., Carlotti, A., Gardair, C., et al. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br J Dermatol 174:4 (2016 Apr), 813–822.
95. [95] O'Rourke, M.G., Bell, J.R., Merkel cell tumor with spontaneous regression. J Dermatol Surg Oncol, 12(9), 1986 Sep 994–6, 1000.
96. [96] Pang, C., Sharma, D., Sankar, T., Spontaneous regression of Merkel cell carcinoma: a case report and review of the literature. Int J Surg Case Rep 7C (2015), 104–108.
97. [97] Swick, B.L., Srikantha, R., Messingham, K.N., Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma. J Cutan Pathol 40:7 (2013 Jul), 623–630.
98. [98] Andea, A.A., Patel, R., Ponnazhagan, S., Kumar, S., DeVilliers, P., Jhala, D., et al. Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status. Hum Pathol 41:10 (2010 Oct), 1405–1412.
99. [99] Nardi, V., Song, Y., Santamaria-Barria, J.A., Cosper, A.K., Lam, Q., Faber, A.C., et al. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res 18:5 (2012 Mar 1), 1227–1236.
100. [100] Lipson, E.J., Vincent, J.G., Loyo, M., Kagohara, L.T., Luber, B.S., Wang, H., et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 1:1 (2013 Jul), 54–63.
101. [101] Asioli, S., Righi, A., de Biase, D., Morandi, L., Caliendo, V., Picciotto, F., et al. Expression of p63 is the sole independent marker of aggressiveness in localised (stage I–II) Merkel cell carcinomas. Mod Pathol 24:11 (2011 Nov), 1451–1461.
102. [102] Stetsenko, G.Y., Malekirad, J., Paulson, K.G., Iyer, J.G., Thibodeau, R.M., Nagase, K., et al. p63 expression in Merkel cell carcinoma predicts poorer survival yet may have limited clinical utility. Am J Clin Pathol 140:6 (2013 Dec), 838–844.
103. [103] Fernandez-Figueras, M.T., Puig, L., Musulen, E., Gilaberte, M., Lerma, E., Serrano, S., et al. Expression profiles associated with aggressive behavior in Merkel cell carcinoma. Mod Pathol 20:1 (2007 Jan), 90–101.
104. [104] Fernandez-Figueras, M.T., Puig, L., Musulen, E., Gilaberte, M., Ferrandiz, C., Lerma, E., et al. Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma. Histopathology 46:6 (2005 Jun), 614–621.
105. [105] Ng, L., Beer, T.W., Murray, K., Vascular density has prognostic value in Merkel cell carcinoma. Am J Dermatopathol 30:5 (2008 Oct), 442–445.
106. [106] Kurzen, H., Kaul, S., Egner, U., Deichmann, M., Hartschuh, W., Expression of MUC 1 and ep-CAM in Merkel cell carcinomas: implications for immunotherapy. Arch Dermatol Res 295:4 (2003 Aug), 146–154.
107. [107] Brunner, M., Thurnher, D., Pammer, J., Heiduschka, G., Petzelbauer, P., Schmid, C., et al. Expression of hedgehog signaling molecules in Merkel cell carcinoma. Head Neck 32:3 (2010 Mar), 333–340.
108. [108] Andea, A.A., Coit, D.G., Amin, B., Busam, K.J., Merkel cell carcinoma: histologic features and prognosis. Cancer 113:9 (2008 Nov 1), 2549–2558.
109. [109] Henderson, S.A., Tetzlaff, M.T., Pattanaprichakul, P., Fox, P., Torres-Cabala, C.A., Bassett, R.L., et al. Detection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma. J Cutan Pathol 41:11 (2014 Nov), 846–852.
110. [110] Iyer, J.G., Storer, B.E., Paulson, K.G., Lemos, B., Phillips, J.L., Bichakjian, C.K., et al. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol 70:4 (2014 Apr), 637–643.
111. [111] Ko, J.S., Prieto, V.G., Elson, P.J., Vilain, R.E., Pulitzer, M.P., Scolyer, R.A., et al. Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of stage III patients. Mod Pathol 29:2 (2016 Feb), 122–130.
112. [112] Skelton, H.G., Smith, K.J., Hitchcock, C.L., McCarthy, W.F., Lupton, G.P., Graham, J.H., Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol 37:5 Pt 1 (1997 Nov), 734–739.
113. [113] Tarantola, T.I., Vallow, L.A., Halyard, M.Y., Weenig, R.H., Warschaw, K.E., Weaver, A.L., et al. Unknown primary Merkel cell carcinoma: 23 new cases and a review. J Am Acad Dermatol 68:3 (2013 Mar), 433–440.
114. [114] Deneve, J.L., Messina, J.L., Marzban, S.S., Gonzalez, R.J., Walls, B.M., Fisher, K.J., et al. Merkel cell carcinoma of unknown primary origin. Ann Surg Oncol 19:7 (2012 Jul), 2360–2366.
115. [115] Foote, M., Veness, M., Zarate, D., Poulsen, M., Merkel cell carcinoma: the prognostic implications of an occult primary in stage IIIB (nodal) disease. J Am Acad Dermatol 67:3 (2012 Sep), 395–399.
116. [116] Chen, K.T., Papavasiliou, P., Edwards, K., Zhu, F., Perlis, C., Wu, H., et al. A better prognosis for Merkel cell carcinoma of unknown primary origin. Am J Surg 206:5 (2013 Nov), 752–757.
117. [117] Moshiri, A.S., Nghiem, P., Milestones in the staging, classification, and biology of Merkel cell carcinoma. J Natl Compr Canc Netw 12:9 (2014 Sep), 1255–1262.
118. [118] Cassler, N.M., Merrill, D., Bichakjian, C.K., Brownell, I., Merkel cell carcinoma therapeutic update. Curr Treat Options Oncol, 17(7), 2016 Jul, 36, 10.1007/s11864-016-0409-1.
119. [119] Tai, P., A practical update of surgical management of Merkel cell carcinoma of the skin. ISRN Surg, 2013, 850797.
120. [120] O'Connor, W.J., Roenigk, R.K., Brodland, D.G., Merkel cell carcinoma. Comparison of Mohs micrographic surgery and wide excision in eighty-six patients. Dermatol Surg 23:10 (1997 Oct), 929–933.
121. [121] Hughes, M.P., Hardee, M.E., Cornelius, L.A., Hutchins, L.F., Becker, J.C., Gao, L., Merkel cell carcinoma: epidemiology, target, and therapy. Curr Dermatol Rep 3 (2014 Jan 22), 46–53.
122. [122] Servy, A., Maubec, E., Sugier, P.E., Grange, F., Mansard, S., Lesimple, T., et al. Merkel cell carcinoma: value of sentinel lymph-node status and adjuvant radiation therapy. Ann Oncol 27:5 (2016 May), 914–919.
123. [123] Paulson, K.G., Iyer, J.G., Byrd, D.R., Nghiem, P., Pathologic nodal evaluation is increasingly commonly performed for patients with Merkel cell carcinoma. J Am Acad Dermatol 69:4 (2013 Oct), 653–654.
124. [124] Mortier, L., Mirabel, X., Fournier, C., Piette, F., Lartigau, E., Radiotherapy alone for primary Merkel cell carcinoma. Arch Dermatol 139:12 (2003 Dec), 1587–1590.
125. [125] Veness, M., Foote, M., Gebski, V., Poulsen, M., The role of radiotherapy alone in patients with Merkel cell carcinoma: reporting the Australian experience of 43 patients. Int J Radiat Oncol Biol Phys 78:3 (2010 Nov 1), 703–709.
126. [126] Poulsen, M., Rischin, D., Walpole, E., Harvey, J., Mackintosh, J., Ainslie, J., et al. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study–TROG 96:07. Clin Oncol 21:23 (2003 Dec 1), 4371–4376.
127. [127] Jouary, T., Leyral, C., Dreno, B., Doussau, A., Sassolas, B., Beylot-Barry, M., et al. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol 23:4 (2012 Apr), 1074–1080.
128. [128] Chen, M.M., Roman, S.A., Sosa, J.A., Judson, B.L., The role of adjuvant therapy in the management of head and neck Merkel cell carcinoma: an analysis of 4815 patients. JAMA Otolaryngol Head Neck Surg 141:2 (2015 Feb), 137–141.
129. [129] Gillenwater, A.M., Hessel, A.C., Morrison, W.H., Burgess, M., Silva, E.G., Roberts, D., et al. Merkel cell carcinoma of the head and neck: effect of surgical excision and radiation on recurrence and survival. Arch Otolaryngol Head Neck Surg 127:2 (2001 Feb), 149–154.
130. [130] Hasan, S., Liu, L., Triplet, J., Li, Z., Mansur, D., The role of postoperative radiation and chemoradiation in Merkel cell carcinoma: a systematic review of the literature. Front Oncol, 3, 2013 Nov 14, 276.
131. [131] Kokoska, E.R., Kokoska, M.S., Collins, B.T., Stapleton, D.R., Wade, T.P., Early aggressive treatment for Merkel cell carcinoma improves outcome. Am J Surg 174:6 (1997 Dec), 688–693.
132. [132] Lewis, K.G., Weinstock, M.A., Weaver, A.L., Otley, C.C., Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol 142:6 (2006 Jun), 693–700.
133. [133] Meeuwissen, J.A., Bourne, R.G., Kearsley, J.H., The importance of postoperative radiation therapy in the treatment of Merkel cell carcinoma. Int J Radiat Oncol Biol Phys 31:2 (1995 Jan 15), 325–331.
134. [134] Mojica, P., Smith, D., Ellenhorn, J.D., Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol 25:9 (2007 Mar 20), 1043–1047.
135. [135] Veness, M.J., Morgan, G.J., Gebski, V., Adjuvant locoregional radiotherapy as best practice in patients with Merkel cell carcinoma of the head and neck. Head Neck 27:3 (2005 Mar), 208–216.
136. [136] Garneski, K.M., Nghiem, P., Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol 57:1 (2007 Jul), 166–169.
137. [137] Ott, M.J., Tanabe, K.K., Gadd, M.A., Stark, P., Smith, B.L., Finkelstein, D.M., et al. Multimodality management of Merkel cell carcinoma. Arch Surg, 134(4), 1999 Apr 388,92; discussion 392–3.
138. [138] Bhatia, S., Storer, B.E., Iyer, J.G., Moshiri, A., Parvathaneni, U., Byrd, D., et al. Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908 cases from the National Cancer Data Base. J Natl Cancer Inst, 108(9), 2016 May 31, djw042.
139. [139] Iyer, J.G., Parvathaneni, U., Gooley, T., Miller, N.J., Markowitz, E., Blom, A., et al. Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. Cancer Med 4:8 (2015 Aug), 1161–1170.
140. [140] Poulsen, M.G., Rischin, D., Porter, I., Walpole, E., Harvey, J., Hamilton, C., et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?. Int J Radiat Oncol Biol Phys 64:1 (2006 Jan 1), 114–119.
141. [141] Saini, A.T., Miles, B.A., Merkel cell carcinoma of the head and neck: pathogenesis, current and emerging treatment options. Onco Targets Ther 8 (2015 Aug 19), 2157–2167.
142. [142] Sharma, D., Flora, G., Grunberg, S.M., Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature. Am J Clin Oncol 14:2 (1991 Apr), 166–169.
143. [143] Desch, L., Kunstfeld, R., Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. J Skin Cancer, 2013, 327150.
144. [144] Iyer, J.G., Blom, A., Doumani, R., Lewis, C., Tarabadkar, E.S., Anderson, A., et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med 5:9 (2016 Jul 19), 2294–2301.
145. [145] Miller, N.J., Bhatia, S., Parvathaneni, U., Iyer, J.G., Nghiem, P., Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options Oncol 14:2 (2013 Jun), 249–263.
146. [146] Voog, E., Biron, P., Martin, J.P., Blay, J.Y., Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85:12 (1999 Jun 15), 2589–2595.
147. [147] Tai, P.T., Yu, E., Winquist, E., Hammond, A., Stitt, L., Tonita, J., et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18:12 (2000 Jun), 2493–2499.
148. [148] Satpute, S.R., Ammakkanavar, N.R., Einhorn, L.H., Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings. J Clin Oncol, 32(Suppl), 2014, 9049.
149. [149] Becker, J., Lorenz, E., Haas, G., Helwig, C., Oksen, D., Mahnke, L., et al. Evaluation of real world treatment outcomes in patients with metastatic Merkel cell carcinoma (MCC) following second line chemotherapy. Ann Oncol, 26(Suppl. 3), 2016, 2602 [in press].
150. [150] Cowey, C., Mahnke, L., Espirito, J., Fox, P., Helwig, C., Oksen, D., et al. Real-world outcomes of patients with metastatic Merkel cell carcinoma treated with second-line or later chemotherapy in a community oncology setting in the United States. Value Health, 19(7), 2016 Nov, A717 http://dx.doi.org/10.1016/j.jval.2016.09.2122.
151. [151] Schildberg, F.A., Klein, S.R., Freeman, G.J., Sharpe, A.H., Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 44:5 (2016 May 17), 955–972.
152. [152] Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:4 (2015 Apr 13), 450–461.
153. [153] Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:17 (2015 Jun 10), 1974–1982.
154. [154] Nghiem, P.T., Bhatia, S., Lipson, E.J., Kudchadkar, R.R., Miller, N.J., Annamalai, L., et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374:26 (2016 June), 2542–2552.
155. [155] Kaufman, H.L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S.P., et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:10 (2016 Oct), 1374–1385.
156. [156] Trinchieri, G., Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:2 (2003 Feb), 133–146.
157. [157] Lyngaa, R., Pedersen, N.W., Schrama, D., Thrue, C.A., Ibrani, D., Met, O., et al. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donors. Clin Cancer Res 20:7 (2014 Apr 1), 1768–1778.
158. [158] Bhatia, S., Miller, N., Lu, H., Ibrani, D., Shinohara, M., Byrd, D.R., et al. Pilot trial of intratumoral (IT) G100, a toll-like receptor-4 (TLR4) agonist, in patients (pts) with Merkel cell carcinoma (MCC): final clinical results and immunologic effects on the tumor microenvironment (TME). ASCO Meet Abstr, 34(Suppl. 15), 2016 May 31, 3021.
159. [159] Brunner, M., Thurnher, D., Pammer, J., Geleff, S., Heiduschka, G., Reinisch, C.M., et al. Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, her-2/neu, mcl-1 and bmi-1 in Merkel cell carcinoma. Mod Pathol 21:7 (2008 Jul), 876–884.
160. [160] Su, L.D., Fullen, D.R., Lowe, L., Uherova, P., Schnitzer, B., Valdez, R., CD117 (KIT receptor) expression in Merkel cell carcinoma. Am J Dermatopathol 24:4 (2002 Aug), 289–293.
161. [161] Hafner, C., Houben, R., Baeurle, A., Ritter, C., Schrama, D., Landthaler, M., et al. Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One, 7(2), 2012, e31255.
162. [162] Loader, D.E., Feldmann, R., Baumgartner, M., Breier, F., Schrama, D., Becker, J.C., et al. Clinical remission of Merkel cell carcinoma after treatment with imatinib. J Am Acad Dermatol 69:4 (2013 Oct), e181–e183.
163. [163] Samlowski, W.E., Moon, J., Tuthill, R.J., Heinrich, M.C., Balzer-Haas, N.S., Merl, S.A., et al. A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a Southwest Oncology Group study (S0331). Am J Clin Oncol 33:5 (2010 Oct), 495–499.
164. [164] Davids, M.S., Charlton, A., Ng, S.S., Chong, M.L., Laubscher, K., Dar, M., et al. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol 27:26 (2009 Sep 10), e97–100.
165. [165] Nathan, P.D., Gaunt, P., Wheatley, K., Bowden, S.J., Savage, J., Faust, G., et al. UKMCC-01: a phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma. ASCO Meet Abstr, 34(Suppl. 15), 2016 May 31, 9542.
166. [166] Shiver, M.B., Mahmoud, F., Gao, L., Response to idelalisib in a patient with stage IV Merkel-cell carcinoma. N Engl J Med 373:16 (2015 Oct 15), 1580–1582.
167. [167] Lin, Z., McDermott, A., Shao, L., Kannan, A., Morgan, M., Stack, B.C. Jr., et al. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma. Cancer Lett 344:2 (2014 Mar 28), 272–281.
168. [168] Kannan, A., Lin, Z., Shao, Q., Zhao, S., Fang, B., Moreno, M.A., et al. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth. Oncotarget 7:6 (2016 Feb 9), 6576–6592.
169. [169] Buder, K., Lapa, C., Kreissl, M.C., Schirbel, A., Herrmann, K., Schnack, A., et al. Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. BMC Cancer, 14(268), 2014 Apr 17 2407–14-268.
170. [170] Papotti, M., Macri, L., Finzi, G., Capella, C., Eusebi, V., Bussolati, G., Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. Semin Diagn Pathol 6:2 (1989 May), 174–188.
171. [171] Fakiha, M., Letertre, P., Vuillez, J.P., Lebeau, J., Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther 6:3 (2010 Jul-Sep), 382–384.
172. [172] di Bartolomeo, M., Bajetta, E., Buzzoni, R., Mariani, L., Carnaghi, C., Somma, L., et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77:2 (1996 Jan 15), 402–408.
173. [173] Veness, M.J., Perera, L., McCourt, J., Shannon, J., Hughes, T.M., Morgan, G.J., et al. Merkel cell carcinoma: improved outcome with adjuvant radiotherapy. ANZ J Surg 75:5 (2005 May), 275–278.